Eugia Pharma

RegulatoryAugust 4, 2026

FDA grants AP status for Leuprolide Acetate ANDA212963 by Eugia Pharma

The FDA has granted Abbreviated Approval (AP) status for Eugia Pharma's ANDA212963 for Leuprolide Acetate.

RegulatoryJuly 31, 2026

EUGIA PHARMA's Tranexamic Acid Supplement Receives FDA AP Status

EUGIA PHARMA's application for a supplement of Tranexamic Acid has received FDA approval status.

RegulatoryJuly 30, 2026

Eugia Pharma submits supplemental application for Pomalidomide (ANDA210249)

Eugia Pharma has submitted a supplemental application for Pomalidomide under ANDA210249, currently marked as AP.

RegulatoryJuly 30, 2026

EUGIA PHARMA's Lenalidomide ANDA213885 Receives AP Status from FDA

EUGIA PHARMA's application for Lenalidomide (ANDA213885) has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 20, 2026

Eugia Pharma's Methotrexate Sodium ANDA210454 Receives AP Status

Eugia Pharma's application for Methotrexate Sodium (ANDA210454) has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 19, 2026

Eugia Pharma submits supplemental application for Zoledronic Acid (ANDA209125)

Eugia Pharma has submitted a supplemental application for Zoledronic Acid under ANDA209125, currently under standard review.

RegulatoryJuly 13, 2026

EUGIA PHARMA's Leuprolide Acetate ANDA Submission Receives AP Status

EUGIA PHARMA has received an Abbreviated New Drug Application (ANDA) approval status for Leuprolide Acetate.

RegulatoryJuly 7, 2026

Eugia Pharma's Tranexamic Acid Supplement Application Receives AP Status from FDA

The FDA has granted an Abbreviated New Drug Application (ANDA) AP status for Eugia Pharma's Tranexamic Acid.

RegulatoryJuly 7, 2026

EUGIA PHARMA receives AP status for POMALIDOMIDE supplement

EUGIA PHARMA has received an Abbreviated Approval (AP) for a supplement related to POMALIDOMIDE.

RegulatoryJune 21, 2026

FDA Accepts Supplemental NDA for Argatroban in Sodium Chloride

The FDA has accepted a supplemental NDA for Argatroban in Sodium Chloride submitted by Eugia Pharma.

Recent signals(10)

FDA grants AP status for Leuprolide Acetate ANDA212963 by Eugia Pharma

EUGIA PHARMA's Tranexamic Acid Supplement Receives FDA AP Status

Eugia Pharma submits supplemental application for Pomalidomide (ANDA210249)

EUGIA PHARMA's Lenalidomide ANDA213885 Receives AP Status from FDA

Eugia Pharma's Methotrexate Sodium ANDA210454 Receives AP Status

Eugia Pharma submits supplemental application for Zoledronic Acid (ANDA209125)

EUGIA PHARMA's Leuprolide Acetate ANDA Submission Receives AP Status

Eugia Pharma's Tranexamic Acid Supplement Application Receives AP Status from FDA

EUGIA PHARMA receives AP status for POMALIDOMIDE supplement

FDA Accepts Supplemental NDA for Argatroban in Sodium Chloride

Upcoming catalysts

Regulatory activity(10)

FDA grants AP status for Leuprolide Acetate ANDA212963 by Eugia Pharma

EUGIA PHARMA's Tranexamic Acid Supplement Receives FDA AP Status

Eugia Pharma submits supplemental application for Pomalidomide (ANDA210249)

EUGIA PHARMA's Lenalidomide ANDA213885 Receives AP Status from FDA

Eugia Pharma's Methotrexate Sodium ANDA210454 Receives AP Status

Eugia Pharma submits supplemental application for Zoledronic Acid (ANDA209125)

EUGIA PHARMA's Leuprolide Acetate ANDA Submission Receives AP Status

Eugia Pharma's Tranexamic Acid Supplement Application Receives AP Status from FDA

EUGIA PHARMA receives AP status for POMALIDOMIDE supplement

FDA Accepts Supplemental NDA for Argatroban in Sodium Chloride

Clinical activity

Competitive activity

Assets

Therapeutic areas

Indications

Get signals before the market moves